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The burden of healthcare-associated Clostridium difficile infection in a nonmetropolitan setting
Abstract
Objective
Objective: Healthcare-associated Clostridium difficile infection (HCA-CDI) remains a major cause of
morbidity and mortality in industrialized countries. However, few data exist on the burden of HCA-CDI in
multi-site non-metropolitan settings. This study examined the introduction of an antimicrobial
stewardship programme (ASP) in relation to HCA-CDI rates, and the effect of HCA-CDI on length of stay
(LOS) and hospital costs.
Methods
Methods: A comparative before-and-after intervention study of patients aged ≥16 years with HCA-CDI
from December 2010 to April 2016 across the nine hospitals of a non-metropolitan health district in New
South Wales, Australia was undertaken. The intervention comprised a multi-site ASP supported by a
clinical decision support system, with subsequent introduction of email feedback of HCA-CDI cases to
admitting medical officers.
Main outcome measures
measures: HCA-CDI rates, comparative LOS and hospital costs, prior use of antimicrobials
and proton pump inhibitors, and appropriateness of CDI treatment.
Results
Results: HCA-CDI rates rose from 3.07 to 4.60 cases per 10,000 occupied bed-days pre-intervention, and
remained stable at 4 cases per 10,000 occupied bed-days post-intervention (P = 0.24). Median LOS (17 vs
six days; P < 0.01) and hospital costs (AU$19,222 vs $7861; P < 0.01) were significantly greater for HCACDI cases (N = 91) than for matched controls (N = 172). Half of the patients with severe HCA-CDI (4/8)
did not receive initial appropriate treatment (oral vancomycin).
Conclusions
Conclusions: HCA-CDI placed a significant burden on the regional and rural health service through
increased LOS and hospital costs. Interventions targeting HCA-CDI could be employed to consolidate the
effects of ASPs.

Disciplines
Medicine and Health Sciences

Publication Details
Bond, S. E., Boutlis, C. S., Yeo, W. W., Pratt, W. A. B., Orr, M. E. & Miyakis, S. (2017). The burden of
healthcare-associated Clostridium difficile infection in a non-metropolitan setting. Journal of Hospital
Infection, 95 (4), 387-393.

Authors
Stuart Bond, Craig S. Boutlis, Wilfred W. Yeo, William Pratt, M E. Orr, and Spiros Miyakis

This journal article is available at Research Online: https://ro.uow.edu.au/ihmri/1044

The burden of healthcare associated Clostridium difficile infection in a nonmetropolitan setting
Stuart E Bond,1,2,3 Craig S Boutlis,4 Wilfred W Yeo,2,3,5 William AB Pratt,2,6 Megan E
Orr,7 Spiros Miyakis.2,3,4
1. Department of Pharmacy, Wollongong Hospital, Illawarra Shoalhaven Local
Health District, Wollongong, New South Wales, Australia
2. School of Medicine, University of Wollongong, Wollongong, New South
Wales, Australia
3. Illawarra Health and Medical Research Institute, University of Wollongong,
Wollongong, New South Wales, Australia
4. Department of Infectious Diseases, Wollongong Hospital, New South Wales,
Australia
5. Division of Medicine, Illawarra Shoalhaven Local Health District,
Wollongong, New South Wales, Australia
6. Department of Medicine, Shoalhaven District Memorial Hospital, Nowra,
New South Wales, Australia
7. Department of Pharmacy, Shoalhaven District Memorial Hospital, Nowra,
New South Wales, Australia

Preliminary results from this study were presented at the 4th APAC Forum: Leading
Healthcare Transformation, Auckland, New Zealand, 23-25 September 2015

Address correspondence to Stuart E. Bond, B.Pharm. Department of Pharmacy,
Wollongong Hospital, Loftus St, Wollongong, New South Wales, Australia, 2500
Ph. Work: + 61 2 4255 1530

Mobile: +61 429944972

Fax +61 2 4222 5430

Email: stuart.bond@health.nsw.gov.au
Abbreviated title: Clostridium difficile infection
Word count: 3729 (including abstract, body text, acknowledgments and references)
Two figures submitted.
Two appendices submitted for online publication.

Abstract
Objective
Clostridium difficile infection is a major cause of healthcare associated diarrhoea in
industrialised countries and is associated with considerable morbidity and mortality.
No data exist on the burden of healthcare associated Clostridium difficile infection
(HCA-CDI) in multisite non-metropolitan settings. This study examined the
introduction of an antimicrobial stewardship program (ASP) in relation to HCA-CDI
rates and the effect of HCA-CDI on length of stay (LOS) and hospital costs.
Methods
A comparative before-and-after intervention study of patients aged 16 years and over
with HCA-CDI from December 2010 to April 2016 across the nine hospitals of a
regional and rural health district in New South Wales, Australia. The intervention
consisted of a multisite ASP supported by a clinical decision support system, with
subsequent introduction of email feedback of HCA-CDI cases to admitting medical
officers. Main outcome measures: HCA-CDI rates; comparative LOS and hospital
costs; prior antimicrobial and proton-pump inhibitor use; appropriateness of CDI
treatment.
Results
HCA-CDI rates were stable at four cases per 10,000 occupied bed days following the
intervention. Median LOS (17 vs. 6 days, P<0.01) and hospital costs (AU$19,222 vs.
$7,861, P <0.01) were significantly greater for HCA-CDI cases (N=91) than for
matched controls (N=172). Half of the patients with severe HCA-CDI (4/8) did not
receive initial treatment concordant with Australian guidelines (oral vancomycin).

Conclusions
HCA-CDI placed a significant burden on our regional and rural health service through
increased LOS and hospital costs. Interventions targeting HCA-CDI could be
employed to consolidate the effects of ASPs.

Keywords: Clostridium difficile infection, antimicrobial stewardship program, clinical
decision support system, health care costs, length of stay

Introduction

Clostridium difficile infection (CDI) is a major cause of healthcare associated
diarrhoea in industrialised countries and is associated with considerable morbidity and
mortality.1 In Australia, the annual incidence of hospital-identified CDI was 4.03
cases/10,000 patient days in 2012.2 Risk is increased by antimicrobial use and/or
immunosuppression.3 Other putative risk factors include gastrointestinal surgery,
gastric acid-suppressive therapy and prolonged hospital stay.3

Healthcare associated Clostridium difficile infection (HCA-CDI) has been associated
with increased length of stay (LOS), additional costs from hospitalisation4 and
antimicrobial treatment,3 and indirect costs such as productivity losses.5

Most antimicrobials have been related to CDI, with lincosamides (e.g. clindamycin),
third generation cephalosporins (e.g. ceftriaxone), and broad-spectrum penicillins
(e.g. amoxicillin/clavulanic acid) showing strong associations.6 Fluoroquinolones
have been particularly associated with the hypervirulent NAP1/027 strain.7 There is
probable association between proton pump inhibitor (PPI) use and CDI, with the
combination of PPIs and antimicrobials carrying a greater risk than either alone.8

Antimicrobial stewardship programs (ASPs) should be employed to reduce the
incidence of HCA-CDI.1 Despite HCA-CDI being an outcome measure for ASPs,

increasing community acquisition of CDI may cloud interpretation of HCA-CDI
rates.2 Antimicrobial stewardship (AMS) interventions targeting HCA-CDI have
predominantly been conducted in metropolitan teaching hospitals, at single sites or
within a defined clinical area.9-13 Very limited data exist on the burden of HCA-CDI
in Australia, particularly in regional and rural settings.14 To our knowledge this is the
first study to examine a multisite ASP in relation to HCA-CDI rates in the nonmetropolitan setting.

The aims of our study were: to describe HCA-CDI rates before and after an ASP; to
measure LOS and hospital costs in HCA-CDI patients across multiple hospital sites;
to compare prior antimicrobial and PPI use in HCA-CDI patients with the background
use; and to assess appropriateness of HCA-CDI antimicrobial treatment according to
guidelines.

Methods

Setting

From December 2010 to April 2016, a comparative before-and-after intervention
study on the burden of HCA-CDI was performed across the nine public hospitals
(1000 total beds) of Illawarra Shoalhaven Local Health District (ISLHD) in south
eastern New South Wales (NSW), Australia. The district services 390,000 residents
across a catchment that begins one hour south of Sydney, and extends 250km along a
coastal strip. The three largest hospitals comprise one principal referral hospital (550
beds), a large acute hospital (150 beds) and a medium acute hospital (100 beds). The
remaining six hospitals are either small acute or mixed sub- and non-acute.15 This
study employed Plan, Do, Study, Act (PDSA) quality improvement methodology.16

Antimicrobial Stewardship

In May and June 2012, an ASP supported by a computerised clinical decision support
system (CDSS; GuidanceMS®17) was uniformly implemented across the district’s
nine hospitals. In addition to the CDSS, the ASP involved a restriction policy,
whereby broad spectrum antimicrobials were only stocked in pharmacy (with supply
contingent on CDSS approval) or specialist areas (i.e. intensive care unit [ICU],
emergency department, haematology/oncology ward). An education campaign

involved regular departmental presentations, and an intranet webpage was established
to improve access to guidelines. Regular AMS rounds occurred at the three largest
hospitals, and an antimicrobial advice telephone hotline was established across the
district to support the smaller hospitals without onsite AMS clinicians. See Figure 1
for the study flowchart. There were no major changes to infection control policies
related to either Clostridium difficile or hand hygiene during the study period.

Following a review of HCA-CDI rates, in April 2013 the AMS team (infectious
diseases doctors and pharmacists) introduced a targeted CDI intervention. The AMS
pharmacist audited all CDI cases for the following: patient demographics, risk factors,
antimicrobial treatment, severe disease,3 ICU admission, surgical intervention, and
NAP1/027 strain. A feedback email was then sent to the attending medical officer
(AMO) within two weeks (Appendix A). Qualitative analysis of email responses
determined the level of acceptance by AMOs. Responses were categorised as clinical
feedback, basic acknowledgment or defensive. The appropriateness of HCA-CDI
treatment3 was assessed during AMS rounds or retrospectively from medical notes.
Results were presented to the AMS, drug and therapeutics, and infection control
committees.

Clostridium difficile laboratory testing

From December 2010, our laboratory protocol subjected all diarrhoeal stools to
Clostridium difficile testing. First line testing targeted glutamate dehydrogenase

(GDH) antigen and toxins A and B (C. Diff Quik Chek Complete®, Techlab,
Blacksburg, VA, USA). If those tests were discordant, then a polymerase chain
reaction (PCR; GeneXpert®, Cepheid, Sunnyvale, CA, USA) test was employed,
which could also detect the NAP1/027 strain.

Effect of HCA-CDI on LOS and hospital costs

LOS and hospital cost analysis was performed only for the three acute hospitals due to
a shortage of matched controls and other confounders for LOS at smaller hospitals
(e.g. nursing home availability, social factors). Definitions for HCA-CDI were: HCAhealthcare facility onset, diarrhoea onset >48 hours after admission; HCA-community
onset, diarrhoea onset in the community or <48 hours after admission, but within four
weeks of last discharge.18 Demographic data for HCA-CDI cases did not differ
significantly between hospitals, or between the two types of HCA-CDI (data not
shown).

A post hoc analysis of LOS and hospital costs was conducted for those HCA-CDI
cases identified from 1st April 2013 to 30th April 2014. Matched controls were
identified from diagnosis-related group (DRG) data19 for HCA-CDI cases (N=103).
Controls were identified from 1st January 2013 to 30th June 2014. Two controls were
matched to each case by site, sex, age (+/- 5 years), and DRG (81 cases). Where two
matched controls were not available, one control was identified (10 cases), resulting
in 91 cases and 172 controls (Figure 1). DRGs were grouped and the most common

DRGs were reported. Additional analysis was performed on those HCA-CDI cases
and controls with LOS of ≥8 days to address time-dependent biases (8 days equalled
the median time to HCA-CDI onset).

Antimicrobial and PPI use

Antimicrobial use within one month prior to diagnosis among HCA-CDI patients was
compared with background antimicrobial use data, regularly collected in Australia as
part of standard surveillance reports. Those data (defined daily doses [DDDs] per
1000 occupied bed days [OBDs]) from the three acute hospitals were derived from the
Australian National Antimicrobial Utilisation Surveillance Program (from pharmacy
software) and the Australian National Antimicrobial Prescribing Survey (point
prevalence survey in November 2013, seasonally corrected, antimicrobial class use as
a percentage of total use). PPI use was also compared with background use (point
prevalence survey 2013).

Statistical analyses

Interrupted time series analysis 20 was used to assess HCA-CDI rates at the three large
hospitals (due to comparability of acute OBD data). Data were included from
December 2010 (earliest time point with current CDI testing methods) to April 2016,
with the intervention point defined as May 2012 (introduction of multisite ASP).

Separate analyses were performed for May 2012- Mar 2013 and April 2013 onwards
(targeted CDI intervention). Since those periods did not reveal any significant
differences (data not shown) the post-intervention period was reported as one interval.
A chi-square test was used for proportions or Fisher’s exact test where appropriate. A
Mann-Whitney U-test was used to compare continuous variables such as LOS and
hospital costs. Stata® Statistical Software Version 14 was used (Statacorp, College
Station, Texas, USA). Significance was accepted as P<0.05.

Ethics

Ethics approval was received from the joint University of Wollongong and Illawarra
Shoalhaven Local Health District (ISLHD) Human Research Ethics Committee,
approval number HE13/137.

Results

Figure 2 shows interrupted time series analysis of monthly HCA-CDI rates. The
model-predicted HCA-CDI rate in December 2010 was 3.07 cases/10,000 OBDs.
Prior to introduction of the ASP, the model-predicted rate was 4.6 cases/10,000
OBDs. Following ASP’s introduction, and including the targeted email intervention,
HCA-CDI rates remained stable at 4 cases/10,000 OBDs. None of those differences
reached statistical significance. Detailed time series data are provided in Appendix B.

During the targeted intervention phase from April 2013 to April 2014, 120 primary
HCA-CDI cases were identified. The median age was 73 years (interquartile range
[IQR] 63-81yrs) and 51/120 patients were male (43%). Antimicrobials one month
prior to HCA-CDI diagnosis were received by 107/120 patients (89%). Severe
disease was identified in 8/120 (7%) cases; there were 8/120 (7%) ICU admissions, no
surgical interventions, and no NAP1/027 strains.

Of the emails sent to AMOs for 120 HCA-CDI cases from April 2013-14, 23
responses were received (19% response rate). Of those responses, 10 contained
clinical feedback, 13 contained basic acknowledgement, and there were no defensive
responses. Examples of clinical feedback responses were: “...in the setting of immune
suppression and...other complications with chemo I am treating C diff…”; and, “the
(antibiotic) was for aspiration… the PPI (was) longstanding…”.

Median LOS was 11 days greater for HCA-CDI patients (N=91; 17 days [IQR 8-27])
than their matched controls (N=172; 6 days [IQR 3-12]; P<0.01). Also, median
hospital cost was AU$11,361 higher for the HCA-CDI group ($19,222 [IQR $7,817 $41,337]) compared to controls ($7,861 [IQR $3,477 - $14,553]; P<0.01). The
median time to onset of HCA-CDI was 8 days (IQR 4-14).

The median hospital cost for 48 HCA-CDI patients with LOS ≥ 8 days was
AU$17,832 (IQR 9,472-28,840) vs. AU$12,563 (9,072-20,086) for 70 controls with
LOS ≥ 8 days (P=0.17). For patients with LOS ≥ 8 days, the median LOS was 16 days
(IQR 10-26) for HCA-CDI cases vs. 15 days (IQR 12-26) for controls. After
excluding non-treated patients (N=6) with available controls (N=11), the difference
between HCA-CDI patients and controls persisted for median LOS (18 vs. 7 days;
P<0.01) and cost (AU$20,245 vs. $8,924; P<0.01). The five most common primary
DRG groups among 263 HCA-CDI cases and controls were: gastrointestinal (N=18
for cases, N=36 for controls), haematological malignancy (N=9, N=17), orthopaedic
surgery (N=8, N=15), abdominal surgery (N=6, N=10), and cardiac (N=5, N=9).

Antimicrobial use among the HCA-CDI group at the three acute hospitals was
compared with background antimicrobial use. Over-represented in HCA-CDI patients
were third generation cephalosporins (e.g. ceftriaxone; 34% of total use in HCA-CDI
patients vs. 11% of background use; P<0.01), beta-lactamase inhibitor combinations
(e.g. piperacillin/tazobactam; 58% vs. 36%; P=0.01), nitroimidazoles (e.g.

metronidazole; 28% vs. 11%; P<0.01), and glycopeptides (e.g. vancomycin; 23% vs.
6%; P<0.01). Under-represented in HCA-CDI patients were beta lactamase resistant
penicillins (e.g. flucloxacillin; 7% vs. 18%; P=0.02), beta lactamase sensitive
penicillins (e.g. benzylpenicillin; 2% vs. 9%; P=0.03), extended spectrum penicillins
(e.g. ampicillin; 14% vs. 33%; P=0.03), macrolides (e.g. azithromycin; 4% vs. 19%;
P<0.01), and tetracyclines (e.g. doxycycline; 4% vs. 38%; P<0.01).

Vancomycin and metronidazole were over-represented in HCA-CDI patients, but are
also recommended for CDI treatment. Those two classes were further analysed. For
vancomycin, the most commonly co-prescribed antimicrobial was
piperacillin/tazobactam (11/25) with febrile neutropenia the commonest known
indication (9/11). Vancomycin use was intravenous in all of those cases. For
metronidazole, the most commonly co-prescribed antimicrobial was ceftriaxone
(13/35), predominantly for abdominal infections (10/13). There was an overall
decrease in use of broad spectrum antimicrobials following implementation of the
multisite ASP (data not shown). PPI use was documented in 83/120 (69%) HCA-CDI
patients compared with 343/730 (47%) patients audited as part of the local 2013 point
prevalence survey (P<0.01).

In non-severe HCA-CDI treated at the acute hospitals (N=95), oral metronidazole was
initiated in 78 (82%) cases. Oral vancomycin plus oral metronidazole was used in
eight (8%) cases, where metronidazole alone would have sufficed.3 No therapy was
given in nine non-severe cases, due to cessation of diarrhoea with or without
identification of an alternative correctable cause. In the severe HCA-CDI group

(N=8), oral metronidazole was initiated in 4 (50%) cases, where oral vancomycin,
intravenous metronidazole or a combination was indicated. In those cases a relevant
AMS intervention was made.

Discussion

Our study describes the relationship between HCA-CDI rates and a multisite ASP
supported by a CDSS, education and antimicrobial restriction combined with targeted
audit and feedback. Implementation of an ASP was temporally associated with stable
HCA-CDI rates. Targeted interventions may help to combat the waning of the initial
impact of a program over time. We found that in an Australian non-metropolitan
setting, LOS and hospital costs were significantly increased in HCA-CDI patients
when compared with matched controls. Increased antimicrobial and PPI use in
patients with HCA-CDI were consistent with previous reports.6, 8 Although the initial
treatment of non-severe HCA-CDI cases predominantly matched guidelines, there
was concerning use of oral metronidazole in half of the severe cases (albeit with small
numbers). This was similar to previous findings elsewhere,21 likely resulting from
under-recognition of severity criteria.3, 22

HCA-CDI has been associated with increased LOS and hospital costs.4 Most studies
evaluating these effects were either epidemiological studies23, 24 or performed in the
metropolitan setting.10 To our knowledge this is the first study to combine evaluation
of the burden of HCA-CDI with multisite ASP implementation in a regional and rural
setting. Comparison with matched controls11, 25 allowed for a pragmatic approach to
identifying additional LOS and hospital costs associated with HCA-CDI. For those
patients with LOS ≥ 8 days, there was a 42% increase in hospital costs in HCA-CDI
patients compared with controls, despite similar LOS in those groups. This

highlighted the increased cost of caring for HCA-CDI patients additional to greater
LOS, and alleviated the potential for time-dependent biases.

There were several limitations to this study. We included all positive Clostridium
difficile tests during the targeted intervention phase, as the frequency of daily
diarrhoeal episodes was unreliably documented. Alternative causes of diarrhoea may
have been present in some patients carrying Clostridium difficile. We could not
attribute the increase in LOS and hospital costs to HCA-CDI alone. Alternative
statistical methods such as multi-state modelling26 to account for time-dependent
biases, and propensity matching4 to accurately estimate the impacts of CDI have been
proposed. To account for those limitations, we applied the case-control methodology
in two additional subsets: the “long-stay” patients (≥8 days, the median time-to-onset
of HCA-CDI) and only those treated for HCA-CDI. Those results were in line with
our primary evaluation, emphasising the high LOS and cost burden of HCA-CDI. As
expected, gastrointestinal DRGs were overrepresented. In some cases the primary
DRG may have been allocated to gastrointestinal due to CDI severity or duration.

Community cases could not be accurately assessed with the current study resources.
Of 120 HCA-CDI cases, only 91 were eventually analysed for LOS and cost.
Assessing the impact on HCA-CDI rates might have been confounded for
antimicrobials (e.g. metronidazole, vancomycin) often given to treat CDI or coadministered with antimicrobials associated with HCA-CDI. Intravenous vancomycin
has been associated with CDI27; however, vancomycin was associated with CDI in
this study only when combined with other antimicrobials. We did not evaluate

appropriateness of prior antimicrobial use, in order to define avoidable HCA-CDI
cases. Detailed demographic data and prior antimicrobial use were not collected for
controls, as this dataset was collected to allow for a post hoc analysis. Using
background antimicrobial and PPI data allowed for larger numbers and accounted for
the potential of bias due to under-reporting of those agents in control patients in
whom CDI was not considered. However, detailed characteristics of patients from
whom the background use data were derived were not available. The largest hospital
accounted for two thirds of the total OBDs; hence its infection rate largely determined
the overall rate. The response rate to emails was only 19%, limiting conclusions about
their impact; however, responses were not requested in the initial email, and still some
useful clinical feedback was received. Due to the hospitals’ geographic disparity,
email remained the most pragmatic feedback method.

Patient complexity in our hospitals may be lower compared with larger metropolitan
hospitals, limiting generalisability to those settings. Further studies combining
evaluation of ASPs with targeted CDI interventions would be useful, particularly in
multisite and non-metropolitan settings. In this study we identified high risk
antimicrobial classes that have formed targets for ongoing AMS activities.

Our study demonstrates the high burden of HCA-CDI in a non-metropolitan setting.
While it confirms the association between high-risk antimicrobial use and HCA-CDI,
it also identifies the possibility of under-recognition of CDI severity criteria during
treatment initiation. Targeted audit and feedback interventions may be a useful way of

consolidating the effects of a multisite ASP, contributing to sustainability, which
remains one of the major challenges of contemporary antimicrobial stewardship.
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Figure legends

Figure 1: Study flowchart.
ASP, antimicrobial stewardship program; CDSS, clinical decision support system;
HCA, healthcare associated; LOS, length of stay; risk factors, anti-peristaltic use,
gastrointestinal surgery, immunosuppression; PPIs, proton pump inhibitors; HCACDI, healthcare associated Clostridium difficile infection; DRG, diagnosis-related
group; background use, whole hospital prevalence data on antimicrobial use

Figure 2: HCA-CDI rates for the three acute hospitals in Illawarra Shoalhaven Local
Health District, Australia from December 2010 to April 2016
Vertical line, implementation of antimicrobial stewardship program; HCA-CDI,
healthcare associated Clostridium difficile infection; OBD, occupied bed day.

Appendix A: Exemplar feedback email to admitting medical officer on Clostridium
difficile infection case

Dear Doctor,

As part of routine antimicrobial stewardship activities we are conducting a
prospective audit into all episodes of C. diff diarrhoea across the district.

Your patient X (MRN: 111111) was diagnosed with C. diff diarrhoea on dd/mm/yyyy.

Potential risk factors for your patient included:

(As appropriate)
•

Proton pump inhibitor use –

•

Anti-peristaltic use –

•

Prior GI surgery –

•

Immunosuppression –

•

Antimicrobial use within one month prior to diagnosis –

Details of antimicrobial treatment of CDI.
I’ve attached a copy of the audit form for your information. Please don’t hesitate to
contact me if you have any questions.
Regards,
AMS pharmacist

Appendix B: HCA-CDI rates before and after implementation of an ASP

Pre-ASP (Dec 2010 to April 2012)
Initial level

Initial trend

p-value

Post-ASP (May 2012 to April 2016)
Change

p-value

in level
HCA CDI per 10,000 OBDs, n
(LCI, UCI)

3.07a

0.09a

(1.51-4.65)

(-0.06-0.24)

0.23

-0.83a
(-2.25-0.58)

Change

p-value

in trend
0.24

-0.08a

0.26

(-0.24-0.07)

Initial level, number of cases of HCA-CDI per 10,000 occupied bed days per month; initial trend, rate of increase per month; change in level,
immediate difference between pre-intervention and post-intervention cases; change in trend, difference between pre-intervention and postintervention trend by month; ASP, antimicrobial stewardship program, detail described in Methods; HCA-CDI, healthcare associated
Clostridium difficile infection, data included for the three large acute hospitals of the health district; OBDs, occupied bed days; LCI, lower 95%
confidence interval; UCI, upper 95% confidence interval; aadjusted for first order autocorrelation;
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